Q32 Bio (QTTB) Other Non-Current Assets (2017 - 2026)
Q32 Bio's quarterly Other Non-Current Assets came in at $647000.0 in Q1 2026, little changed year-on-year from $647000.0 in Q1 2025, and little changed quarter-over-quarter from $647000.0 in Q4 2025.
Q32 Bio has reported Other Non-Current Assets for 10 years, with the latest figure at $647000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets changed 0.0% year-over-year to $647000.0; the trailing twelve-month figure through Mar 2026 stood at $647000.0 (changed 0.0% YoY), and the FY2025 full-year result was $647000.0, up 457.76% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $647000.0, roughly flat from $647000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $5.6 million in Q1 2023, with the low at $23000.0 in Q4 2023.
- Average Other Non-Current Assets over 5 years is $1.6 million, with a median of $647000.0 recorded in 2024.
- Year-over-year, Other Non-Current Assets jumped 1946.01% in 2023 and slumped 99.29% in 2024.
- Tracing QTTB's Other Non-Current Assets over 5 years: stood at $276000.0 in 2022, then sank by 91.67% to $23000.0 in 2023, then surged by 404.35% to $116000.0 in 2024, then surged by 457.76% to $647000.0 in 2025, then changed by 0.0% to $647000.0 in 2026.
- The last three Other Non-Current Assets figures came in at $647000.0 (Q1 2026), $647000.0 (Q4 2025), and $647000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Q32 Bio | 162.94 Mn | 112.19 Mn | - | 647,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 647,000.00 |
| Dec 31, 2025 | 647,000.00 |
| Jun 30, 2025 | 647,000.00 |
| Mar 31, 2025 | 647,000.00 |
| Dec 31, 2024 | 116,000.00 |
| Sep 30, 2024 | 40,000.00 |
| Jun 30, 2024 | 647,000.00 |
| Mar 31, 2024 | 647,000.00 |
| Dec 31, 2023 | 23,000.00 |
| Sep 30, 2023 | 5.65 Mn |
| Jun 30, 2023 | 5.65 Mn |
| Mar 31, 2023 | 5.65 Mn |
| Mar 31, 2022 | 276,000.00 |
| Dec 31, 2021 | 1.95 Mn |
| Sep 30, 2021 | 1.27 Mn |
| Jun 30, 2021 | 1.27 Mn |
| Mar 31, 2021 | 1.27 Mn |
| Dec 31, 2020 | 1.27 Mn |
| Sep 30, 2020 | 1.27 Mn |
| Jun 30, 2020 | 1.27 Mn |
| Mar 31, 2020 | 1.27 Mn |
| Dec 31, 2019 | 1.27 Mn |
| Sep 30, 2019 | 1.27 Mn |
| Jun 30, 2019 | 1.27 Mn |
| Mar 31, 2019 | 1.27 Mn |
| Dec 31, 2018 | 1.77 Mn |
| Sep 30, 2018 | 1.79 Mn |
| Jun 30, 2018 | 1.79 Mn |
| Mar 31, 2018 | 1.77 Mn |
| Dec 31, 2017 | 1.80 Mn |